Last $0.61 USD
Change Today +0.01 / 1.67%
Volume 82.3K
NYMX On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 10:37 AM 11/28/14 All times are local (Market data is delayed by at least 15 minutes).

nymox pharmaceutical corp (NYMX) Snapshot

Open
$0.64
Previous Close
$0.60
Day High
$0.64
Day Low
$0.58
52 Week High
12/2/13 - $7.10
52 Week Low
11/14/14 - $0.45
Market Cap
21.4M
Average Volume 10 Days
834.7K
EPS TTM
$-0.15
Shares Outstanding
35.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NYMOX PHARMACEUTICAL CORP (NYMX)

nymox pharmaceutical corp (NYMX) Related Bloomberg News

View More Bloomberg News

nymox pharmaceutical corp (NYMX) Related Businessweek News

No Related Businessweek News Found

nymox pharmaceutical corp (NYMX) Details

Nymox Pharmaceutical Corporation, a biopharmaceutical company, is engaged in the research and development of products for the aging population. It provides NicAlert and TobacAlert products that use urine or saliva to detect use of and exposure to tobacco products, as well as AlzheimAlert, a proprietary urine assay that aid physicians in the diagnosis of Alzheimer’s disease. The company’s products under development include NX-1207, which in Phase III clinical trials for the treatment of benign prostatic hyperplasia and localized prostate cancer, as well as in human clinical trials to treat hepatocellular carcinoma; and NXC-4720, an anti-bacterial agent for the treatment of E. coli O157:H7 bacterial contamination in hamburger meat and other food and drink products, and for the treatment of urinary tract and other bacterial infections in humans. Its products under development also comprise NXB-4221 for the treatment of chronic and persistent urinary tract infections; NXB-5886 for the treatment of streptococcal infection; and NXT-1021 for the treatment of staphylococcal infection. In addition, the company is involved in the research and development of drugs at various treatments for Alzheimer's disease and other indications; drugs for the treatment of Alzheimer’s disease that targets spherons; and neural thread protein-based drugs. Further, it develops proprietary diagnostic products; has U.S. patents for using saliva to determine cholesterol levels and for a method of testing for osteoporosis; and owns patent rights to several novel biochemical indicators for Alzheimer’s disease. The company markets its tests through marketing arm and distributors in North America, Europe and Asia, as well as TobacAlert through online at tobacalert.com. Nymox Pharmaceutical Corporation has license and collaboration agreement with Recordati Ireland Ltd. for the development and commercialization of NX-1207. The company was founded in 1989 and is headquartered in Saint-Laurent, Canada.

nymox pharmaceutical corp (NYMX) Top Compensated Officers

Founder, Chairman, Chief Executive Officer, P...
Total Annual Compensation: $290.0K
Chief Information Officer, General Counsel, D...
Total Annual Compensation: $188.0K
Senior Manager of Global Sales & Marketing
Total Annual Compensation: $140.0K
Compensation as of Fiscal Year 2013.

nymox pharmaceutical corp (NYMX) Key Developments

Bernard M. Gross, P.C. Files Class Action Lawsuit Against Nymox Pharmaceutical Corporation

Law Offices Bernard M. Gross, P.C. filed a class action lawsuit in the United States District Court, District of New Jersey, 14-cv-07331, on behalf of purchasers of Nymox Pharmaceutical Corporation common stock between January 31, 2011 and November 2, 2014. This matter is pending before the Honorable Jose L. Linares. The lawsuit filed against the company and Paul Averback, the president, director and chairman of the company, alleges violations of the federal securities laws based on their failure to disclose material information affecting the Phase 3 clinical trials for Nymox's proprietary drug NX-1207 for the treatment of benign prostatic hyperplasia.

Nymox Pharmaceutical Corporation expected to report Q3 2014 results on November 28, 2014. This event was calculated by Capital IQ (Created on November 22, 2014).

Nymox Pharmaceutical Corporation expected to report Q3 2014 results on November 28, 2014. This event was calculated by Capital IQ (Created on November 22, 2014).

Nymox Pharmaceutical Corporation Announces Unaudited Consolidated Financial Results for the Third Quarter and Nine Months Ended September 30, 2014

Nymox Pharmaceutical Corporation announced unaudited consolidated financial results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported revenues were $735,529 compared to $743,288 a year ago. Loss from operating activities was $697,516 compared to $1,002,617 a year ago. Net loss and comprehensive loss attributable to the equity holders of the corporation was $688,206 or $0.02 basic and diluted per share compared to $1,020,387 or $0.03 basic and diluted per share a year ago, is mainly due to a decrease of $515,417 in clinical trial expenditures, a decrease of $19,699 in stock compensation charges, net of a decrease of $292,205 in research tax credits. . For the nine months, the company reported revenues were $2,220,372 compared to $2,421,520 a year ago. Loss from operating activities was $4,061,001 compared to $3,571,006 a year ago. Net loss and comprehensive loss attributable to the equity holders of the corporation was $4,101,293 or $0.12 basic and diluted per share compared to $3,591,682 or $0.11 basic and diluted per share a year ago. Cash flows used in operating activities was $4,391,894 compared to $5,220,228 a year ago. Additions to property and equipment was $3,529 compared t o $5,244 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NYMX:US $0.61 USD +0.01

NYMX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $44.68 USD +0.425
Amorfix Life Sciences Ltd C$0.11 CAD -0.01
Laboratory Corp of America Holdings $104.62 USD +2.47
OraSure Technologies Inc $9.36 USD +0.13
Quest Diagnostics Inc $65.16 USD +0.73
View Industry Companies
 

Industry Analysis

NYMX

Industry Average

Valuation NYMX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.7x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NYMOX PHARMACEUTICAL CORP, please visit www.nymox.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.